SYT-510
General Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD)
Phase 1Active
Key Facts
Indication
General Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD)
Phase
Phase 1
Status
Active
Company
About Synendos Therapeutics
Synendos Therapeutics is a Swiss, private biotech advancing a novel class of drugs called Selective Endocannabinoid Reuptake Inhibitors (SERIs) to treat major neuropsychiatric disorders. The company's lead asset, SYT-510, has completed Phase 1 trials with positive results and is poised to enter Phase 2 development for conditions such as GAD and PTSD. Founded on pioneering academic research, Synendos is backed by a syndicate of European life science investors and aims to provide a new, physiology-based treatment modality for the vast, underserved mental health market.
View full company profile